A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

• Status: Completed
• Trial end date: 2007-06-08
• Target enrollment: 0
• Participant gender: All

Summary

This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bupropion

Criteria

Inclusion Criteria:

• Healthy males or females.

• Non-smokers

• Agree to remain in the clinic for the time defined in the protocol.

• Normal ECG.

Exclusion Criteria:

• Any serious medical disorder or condition.

• Any history of an endocrine disorder.

• Any clinically significant laboratory abnormality.

• History of psychiatric illness.

• Any history of suicidal attempts or behavior.

• Risk factors for precipitation of angle closure glaucoma or elevated IOP.

• Inability to refrain from use of contact lenses during the study days, if correction is required.

• Self-administered Beck Depression Inventory II scale total score greater than 9, and a suicide question score of greater than zero.

• Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure - Women having a positive serum HCG pregnancy test at screening, a positive urine pregnancy test before admission to the Unit during the in-house periods, who are not willing to use acceptable methods of contraception or who are lactating or planning to become pregnant within the three months following the screening visit.